FOXP3 and cancer: Using multiple gene markers together to accurately identify Tregs in cancer, such as FOXP3 + BLIMP115 or FOXP3 + CTLA4,16 has demonstrated a more thorough evaluation of Tregs in recent years.13,15 Our current study also uses multiple markers to define Tregs enrichment rather than FOXP3 expression alone,17 but our primary interest was rather to examine the global microenvironmental context through which Tregs may be associated with differing clinical outcomes such as chemosensitivity and overall survival (OS).